Cleveland Clinic urologists and pediatric oncologists teamed up to create a protocol for the collection and storage of testicular tissue from prepubescent males undergoing gonadotoxic treatments.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Preclinical studies have shown that autologous transplantation of spermatogonial stem cells (SSCs) from CTT has the potential to restore spermatogenesis in animal models. While semen cryopreservation is the standard of care in postpubertal boys and adult men at risk for infertility following gonadotoxic treatment, no options currently exist for prepubescent boys not yet producing sperm.
Sarah Vij, MD, a urologist in Cleveland Clinic’s Glickman Urological & Kidney Institute, is leading the investigation alongside, Audrey Rhee, MD, a pediatric urologist, also of the Glickman Institute, and Seth Rotz, MD, and Stefanie Thomas, MD, pediatric oncologists in Cleveland Clinic Children’s.
Dr. Vij, who leads Cleveland Clinic’s Center for Male Fertility, says their goal is to develop a streamlined storage process and have the tissue available for future use when research and technologies have advanced enough to support transplantation of SSC. “Although we do not yet have formal protocols to develop sperm from spermatogonial stem cells in humans, there is hope that this will be available by the time these children are ready to grow their families,” she says
The primary aims of the study are as follows:
- Obtain and store testicular tissue for future use in patients undergoing gonadotoxic therapies who are not able to provide a semen sample.
- Collect testicular tissue specifically for future research initiatives.
- Assess the effect of testicular tissue cryopreservation on levels of parental distress during and after cancer treatment.
It’s never too early to have the fertility-preserving conversation
Advances in pediatric cancer treatment have led to a greater than 80% survival rate at least five years post-treatment. As a result, it’s critical to manage the longer-term effects of cancer treatment on quality of life. This, of course, includes fertility, explains Dr. Rotz. He leads the Fertility Preservation Program at Cleveland Clinic Children’s.
Every patient encounter is different, and age, sex, and treatment are all variables that shape the fertility-preserving conversation, he says. “Regardless of the patient’s age, our goal is to have a conversation about fertility and infertility and potential fertility preservation options with all of our new cancer diagnosis patients before we start therapy. It’s never too early.”
He continues, “For some patients and families, having that conversation about fertility can provide some solace. You’re talking about life after treatment, which can be a hopeful dialogue and alleviate some distress, as difficult as those conversations may be.”
The team hopes to capture this data systematically to understand the association between parent experience measures and determine if TTC plays a role in reducing parental distress and/or increases parental hope.
“Yes, CTT is still experimental. It’s still in the research realm, but the data published about its utility in primates is promising. We’re not quite there yet in humans, but I think we will be. The science is moving really quickly,” says Dr. Vij.
The VeloSano Impact Award will support this work and offer collection at no cost to patients. “We are really excited about this and again hope that we can offer it soon.”